Biotransplant Plans 1st US IND By Year-End
BioTransplant, a US biotechnology company based in Charlestown, Massachusetts, has revealed in a prospectus for an initial public offering that it plans to file an Investigational New Drug application in the USA for its anti-rejection monoclonal antibody, BTI-322, by the end of the year. BTI-322 is already being tested in a European clinical trial.
Preliminary data from this trial will be used in support of the US IND, said the company. This data has revealed that 10 out of 11 patients treated with the antibody experienced a reversal of their acute kidney rejection episodes. Three of these patients were refractory to all other available therapies, noted the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze